Sarepta Therapeutics (Nasdaq: SRPT) and Summit Therapeutics plc (Nasdaq: SMMT) announced that they have entered into an exclusive license and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE